Patient and physician education is the next challenge to change the treatment paradigm for drug-resistant hypertension, Citi Research analyst Joanne Wuensch said.

NeuroOne will get $3 million upfront for an exclusive license to distribute its radiofrequency ablation system designed to treat neurological disorders such as epilepsy and Parkinson's disease.

Interactions between these as-yet hypothetical particles and neutron stars' strong magnetic field would produce photons that ...

In the first 15 patients, radiofrequency ablation was shown to reduce pain scores in most patients with pancreatic cancer.

Statement 25: Clinicians should consider thermal ablation as an alternate approach for the management of cT1a solid renal masses <3 cm in size. For patients who elect thermal ablation, a percutaneous ...

NeuroOne announced today that it executed an amendment to its existing distribution agreement with Zimmer Biomet.

Autonomix Medical, Inc. AMIX shared positive preliminary results from its first five lead-in patients in a proof-of-concept trial. The trial assesses the safety and effectiveness of Autonomix's ...

Developed in collaboration with the Max Planck Institute for Plasma Physics specifically for the Wendelstein 7-X stellarator, ...

A Chinese study suggested that cold weather may make people more susceptible to myocardial infarction with non-obstructive ...

The hospital's Neurosciences Center successfully removed a drug-resistant epileptic focus responsible for severe seizures in ...

Medtronic (NYSE:MDT) today announced new, long-term study data further supporting its Symplicity Spyral renal denervation ...